News - 3.5mm Study In Women's Health
Covalent Group, Inc. to Conduct Additional $3.5 Million Development Studies In Women's Health, Dermatology and Infectious Diseases
WAYNE, Pa., Nov. 18 /PRNewswire/ -- Covalent Group, Inc. (Nasdaq: CVGR) today announced signing contracts with an aggregate value of $3.5 million.
The scope of the clinical development studies involves efficacy and safety of drugs, medical devices and biologics in multiple therapeutic areas including Women's Health, Dermatology and Infectious Disease.
Kenneth M. Borow, M.D., President and Chief Medical Officer commented, "We are especially pleased to have been awarded these new studies because they represent repeat business from our existing client base. The new work adds to Covalent's reputation of providing state of the art solutions and a high level of service to meet the needs of our clients. Furthermore, the new studies broaden the company's profile in the conduct of clinical trials encompassing a wide variety of therapeutic approaches for multiple disease states."
Covalent provides drug development services and health management solutions to pharmaceutical, biotechnology, and device manufacturers as well as managed care organizations. To aid its customers, Covalent has developed several currently available proprietary products utilizing interactive speech recognition technology including TeleTrial(R), for use in clinical trials, and Virtual HouseCall(R), a disease assessment system.
This press release contains forward-looking statements...... |
